anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In recognition of the emerging social and scientific research related to assessing the complex relationships between self-identified race, ancestral origin and the genetic components of diseases, it is important to study physicians and other health professionals knowledge of human genetic variation and how they interpret and apply race, ethnicity and human genetic variation in their clinical decision making. Primary care physicians will be responsible for the translation of new genomic knowledge, including the use of pharmacogenomic and multiplex genetic testing in clinical practice. Understanding health professionals knowledge, beliefs and practices will provide important data for furthering health services and research. The Physicians Understanding of Human Genetic Variation study (PUHGV) is a three-phase, mixed-method study using both qualitative (focus groups and semi-structured interviews) and quantitative methods (web-based survey). The first phase of the study used qualitative methods to investigate racial and ethnic differences in how physicians understand and use genetics, race and ethnicity in their practice and to assist in developing the Health Professionals Genetic Education Needs Exploration survey instrument (HP GENE). Bonham and Sellers developed and piloted the Human Genetic Variation-Health Professionals Knowledge, Beliefs, and Use Scales (HGV-HP) to measure physicians knowledge of human genetic variation (HGV-HP Knowledge), beliefs about biologic and genetic differences based upon their patients race and ethnicity (HGV-HP Beliefs), and use of these constructs in their clinical decision making approaches (HGV-HP Use). The HGV-HP Scales are a component of the larger HP GENE survey instrument. The second phase of the study piloted these instruments with a random sample of United States general internists from diverse racial and ethnic backgrounds and geographic areas of the United States to assess the psychometric properties of the scales and investigate the role of incentives in recruiting physicians to participate in web surveys. Informed by the pilot testing of the instrument, the third phase of this study is to conduct a national survey using the instrument and scales with health professionals from different health disciplines.
Up to 230 patients who benefited from the core study treatment (imatinib or nilotinib), at Investigator's discretion, were enrolled into this extension study. The patients continued receiving the open-label drugs that they were taken by the end of core study. Treatment arms in the core study were retained. No crossover between the arms was allowed.

The extension study started from the first patient last dose date in the core study and ends at the time of nilotinib was commercially available in China as a first line treatment. Eligibility evaluations were given for each patient before the enrollment. Follow-up visits at a frequency of 6 months were required to report AE, SAE and pregnancy only. No efficacy data were collected in the extension study since full efficacy had already been analyzed in the core study.
The typical rehabilitation of walking difficulties for people with MS has included practice walking. In general, this includes training to build walking endurance by having the person with MS walk until he/she becomes tired and needs to stop. Although this model has been used successfully to treat people with other diagnoses, it has limited effectiveness in improving walking ability and endurance in people with MS because of fatigue. Recently, a different model has been considered: intermittent or interval walking training. Interval walking training is organized such that seated rest breaks are intentionally interspersed between walking training bouts that end before the person with MS becomes too tired to continue. Exploratory research has shown that people with MS can walk faster and farther when using interval walking training, and may have more improvements in walking ability and endurance after using interval walking training. This study will compare the effectiveness of the traditional model of continuous walking training to the promising new model of interval walking training. This will help to determine whether interval or continuous walking training is superior in improving walking ability and endurance in people with MS.
A pulp material that comprises a fibrous protein fiber is suitable for incorporation into paper or paper composites. The fibrous protein of the fibrous protein fiber is typically a keratin, fibrin, collagen, or elastin. Preferably, the fibrous protein is a collagen, such as a β-keratin. The β-keratin can be obtained from avian feathers, such as chicken feathers. The pulp material can further comprise at least one additive such as mordants. dyes. binders. foaming agents. hardeners. chemical sizing agents, fillers. wetting agents. plant fibers, or animal fibers. The pulp material can be treated with a crosslinking agent or an oxidizing agent. Other aspects of the invention include a biodegradable polymer comprising the pulp material and a filter comprising the pulp material. Still another aspect of the invention is a composite material comprising: (1) the pulp material; and (2) a fiber selected from the group consisting of an animal fiber and a plant fiber. Still another aspect of the invention is a multilayer material comprising: (1) a first layer that is the pulp material; and (2) a second layer including a material selected from the group consisting of paper and a biopolymer.
Post-Acute Sequelae of COVID-19 or Long COVID becomes evident some weeks to months following acute COVID-19. Symptoms include cognitive impairment and varying degrees of memory loss with no definitive etiologies or efficacious therapies forthcoming even after four years of the SARS-Cov2 pandemic virus. The aim of this review is to demonstrate the important role of α7 nicotinic acetylcholine receptors in both acute COVID-19 and Long COVID. Evidence presented implicates immune mechanisms stimulated by SARS-Cov-2 S-protein fragment 674-685 that possesses homology with α7-specific ligands. Cognitive dysfunctions observed in Long COVID patients may be derived from anti-idiotypic α7-specific antibodies stimulated by (674-685)-specific antibodies. Therapeutic interventions capable of neutralizing these antibodies and restoring full functions of α7 nicotinic acetylcholine receptors appear to be of paramount importance in post-acute sequelae of COVID-19.
Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Tendinopathy is a common injury among athletes, where the incidence reaches 50%. Nevertheless, industrial workers as well as sedentary subjects may also undergo this pain condition.

Achilles tendon is a frequent lower-limb tissue where tendinopathy may arise. Achilles tendinopathy risk factors have been detailed, such as: age, mechanical axis deviation of lower limbs, excessive training load dosage, and type of work activity. The middle portion of the tendon is the area where Achilles tendinopathy is most likely to be located. Interestingly, correlation between pain severity and the degree of tissue degeneration by imaging diagnosis is hardly showed in chronic tendinopathy conditions. Thus, chronic tendinopathy pain may be mediated not only by peripheral but by central mechanisms.

Percutaneous Therapeutic Electrolysis (EPTE® System; Manual EPTE, 2014 IONCLINICS \& DEIONIC, S.L.) is an electronic device that enables to treat accurately, guided by an ultrasound, the tendon injured area by penetrating the skin with an acupuncture needle. A galvanic current goes through the device to the needle so that the first stage of physiological regenerative process may be obtained. That is due to a chemical reaction that leads to a controlled alkaline burn into the injured tissue and a subsequent basification of extracellular medium. That elicits an inflammatory response; the destroyed tissue is metabolized by phagocytosis process. Design: Randomized Controlled Clinical Trial. Objectives: To know the effectiveness of Percutaneous Therapeutic Electrolysis (EPTE®) versus a sham intervention at improving pain and function in patients who undergo Achilles Chronic Tendinopathy, and to determine the efficiency of Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle versus Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle at improving pain and function in patients who undergo Achilles Chronic Tendinopathy. Participants: patients diagnosed with Achilles Chronic Tendinopathy. Setting. Infanta Leonor Hospital, Madrid, Spain. Experimental intervention: Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec versus bipolar needle. Sham intervention: the guide tube of the needle contacted with the skin and the electrolysis device remained switched on to simulate its functioning.
The invention discloses a traditional Chinese medicine composite for treating cold-dampness pattern oesophageal carcinoma, which is prepared by the following crude drugs by weight part: A. 10-15 partsof green tangerine orange peel, 10-15 parts of pericarpium citri reticulatae, 6-10 parts of fructus evodiae, 5-8 parts of agilawood, 3-6 parts of rhizoma pinellinae praeparata powder; B. 10-15 partsof asarum, 25-30 parts of fructus aurantii, 10-15 parts of radices sileris, 15-20 parts of ligusticum wallichii, 8-10 parts of platycodon grandiflorum and 25-30 parts of pachyrhizua angulatus. Vomiting drug prepared by green tangerine orange peel, pericarpium citri reticulatae, fructus evodiae, agilawood, and rhizoma pinellinae praeparata powder is taken singly for 1-2 times with 2-3g every time,stubborn phlegm and waste in esophagus and stomach are expelled from the mouth. In B preparation, asarum is taken as a main constituent, fructus aurantii and radices sileris are taken as subject constituents, ligusticum wallichii and platycodon grandiflorum are used as assisting constituents, and pachyrhizua angulatus is used for promoting the drug effect. By vomiting the stubborn phlegm and wastein esophagus and stomach, cold dissipating, blood stasis in brain vessels, regulating vital energy and promoting the circulation of qi, the cold-dampness pattern oesophageal carcinoma is treated. Thetraditional Chinese medicine composite for treating cold-dampness pattern oesophageal carcinoma has special medicine compatibility, skilful mediation and obvious effect, and has remarkable effect ontreating early-stage and middle-stage cold-dampness pattern oesophageal carcinoma, and has good treating effect, low treating cost and no side effect.
PCT No. PCT/EP94/04230 Sec. 371 Date Aug. 18, 1995 Sec. 102(e) Date Aug. 18, 1995 PCT Filed Dec. 14, 1994 PCT Pub. No. WO95/18091 PCT Pub. Date Jul. 6, 1995   <IMAGE>  (I)  The invention relates to compounds of formula (I), R1 and R2, each independently of the other, are selected from lower alkyl that is unsubstituted or substituted by one or more fluorine atoms which are not linked to the carbon atom of R1 or R2 bonding the nitrogen; from lower alkenyl wherein the double bond does not originate from the carbon atom that is bonded to a nitrogen bonding R1 or R2; from lower alkynyl wherein the triple bond does not originate from the carbon atom that is bonded to a nitrogen bonding R1 or R2; from cycloalkyl; and from cycloalkyl-lower alkyl; with the proviso that not more than one of the two radicals R1 and R2 is methyl; or salts thereof. The mentioned compounds are pharmacologically active against disorders that are responsive to a recuction in intracellular polyamines, such as tumours or protozoal diseases.
Subjects administered standard of care + narsoplimab dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
INTRODUCTION: Although low-energy pelvic fractures seldom present with significant hemorrhage, early recognition of at-risk patients is essential. We aimed to identify predictors of transfusion requirements in this cohort.
METHODS: A 7-y retrospective chart review was performed. Low-energy mechanism was defined as falls of ≤5 feet. Fracture pattern was classified using the Orthopedic Trauma Association/Arbeitsgemeinschaft für Osteosynthesefragen system as A, B, or C. Primary outcome was transfusion of ≥2 units of packed red blood cells in the first 48 h. Univariable analysis and logistic regression analysis were performed. A P value ≤0.05 was considered significant.
RESULTS: Five hundred forty six patients were included with median (interquartile range) age of 86 (79-91) and median (interquartile range) Injury Severity Score of 5 (4-8). Five hundred forty one (99%) had type A fractures. Twenty six (5%) had the primary outcome and 17 (3%) died. Logistic regression found that systolic blood pressure <100 mmHg at any time in the Emergency Department, Injury Severity Score, and pelvic angiography were predictors of the primary outcome. Seventeen percent of those who had the primary outcome died compared with 2% who did not (P = 0.0004). Three hundred sixty four (67%) received intravenous contrast for computerized tomography scans and of these, 44 (12%) had contrast extravasation (CE). CE was associated with the primary outcome but not mortality.
CONCLUSIONS: Hypotension at any time in the Emergency Department and CE on computerized tomography predicted transfusion of ≥2 units packed red blood cells in the first 48 h in patients with low-energy pelvic fractures.
Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index \> 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
For part 2 dose selection optimization, two dose levels will be selected by the Safety Review Committee (SRC) based on review of all available data on safety, tolerability, PK, PD, and preliminary efficacy from part 1. The dose selection optimization will include only patients with R/R DLBCL and will randomize 1:1 approximately 30 new patients at the two selected dose levels (15 patients to each of the two selected dose levels) before declaring the RP2D. Assessment of PK/PD of SP-3164 will be included in part 2 dose selection optimization.
Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
Participants will undergo an 8-week WBV therapy program using a Dynatronics VF5 Model vibration platform. Each session will last 4 minutes, with vibration frequencies progressively increased from 25 Hz to 40 Hz without rest intervals.
Cryotherapy is a resource applied thermal rehabilitation in order to reduce skin temperature and muscle as well as nerve conduction velocity, and promotes vasoconstriction of arteries and veins resulting in decreased blood flow. Thus, this study aims to evaluate neuromuscular and biomechanical assess hemodynamic and autonomic cardiovascular, and investigate the occurrence of changes in conduction velocity due to the superficial blood cryotherapy by immersion of the forearm. The study will be conducted in 40 volunteers, female, between 18 and 30 years, university, healthy. They will be divided into two groups of 20 volunteers, the group immersion cryotherapy (GI) and control group (CG). For immersion cryotherapy group (GI), individuals will be the right arm to the elbow immersed in a container of water at 6°C ± 2°C for 15 minutes. In the control group (CG), volunteers will remain at rest with the right arm in the same position within a vessel containing water at a temperature indifferent for the same period of 15 minutes. The temperature analysis is performed using a infrared thermographer, muscular strength and synergism will be evaluated by a load cell connected to the electromyograph to examine muscle activation of wrist flexors and extensors, serratus anterior, upper and middle trapezius. The records beat to beat blood pressure and heart rate for cardiovascular autonomic and hemodynamic evaluation will be carried out by means of equipment and Finometer electrocardiogram, respectively, before and after application of cryotherapy. In turn, the data of blood flow velocity will be collected by means of Doppler Ultrasound. The results will be processed and analyzed using descriptive statistics, submitted to a linear regression model with mixed effects (fixed and random effects), with p≤0.05.
PURPOSE OF REVIEW: Gastrointestinal mucositis (GIM) is a significant complication of cancer therapy. Whilst inflammation is a central feature of GIM, studies attempting to mitigate mucosal damage via this mechanism are scarce. This review describes the relation between GIM, local and systemic inflammation, and the microbiome and its metabolites, and explores recent research on therapeutics that target this relationship.
RECENT FINDINGS: Recent literature underscores the pivotal role of inflammation in GIM, elucidating its bidirectional relation with disturbance of the gut microbiota composition and intestinal permeability. These events cause a heightened risk of bloodstream infections and lead to systemic inflammation. While studies investigating risk prediction models or therapeutics targeting GIM-related inflammation remain scarce, results have shown promise in finding biomarkers and alleviating GIM and its accompanying clinical symptoms.
SUMMARY: The findings underscore the important role of inflammation and the microbiome in GIM. Understanding the inflammatory pathways driving GIM is crucial for developing effective treatments. Further research is needed using genomics, epigenomics, and microbiomics to explore better risk prediction models or therapeutic strategies aimed at mitigating GIM-related inflammation.
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by tissue heterogeneity and high postoperative recurrence risk. This study aims to employ cytokine analyses to identify serum biomarkers associated with postoperative CRSwNP recurrence and elucidate underlying recurrent mechanisms.
METHODS: A prospective cohort study was conducted on CRSwNP patients undergoing functional endoscopic sinus surgery. Serum and tissue samples were collected and analyzed for multiple cytokines. Participants were followed for 3 years and categorized into recurrent and non-recurrent groups. Cytokine profiles were compared, and potential markers for recurrence were further assessed. Macrophage migration inhibitory factor (MIF) expression in macrophages was modulated, and their polarization and cytokine secretion were assessed.
RESULTS: In the discovery cohort (21 recurrent and 40 non-recurrent patients), circulating cytokine profiles differed significantly, with 8 cytokines showing differential expression between the two groups. Among them, serum eotaxin, MIF, RANTES, and TRAIL exhibited promise in predicting recurrence. In the validation cohort (24 recurrent and 44 non-recurrent patients), serum eotaxin, MIF, and TRAIL levels were higher in recurrent cases. Tissue MIF was elevated in recurrent cases and had a strong predictive value for recurrence. Moreover, tissue MIF was co-expressed with CD206 in recurrent cases. Mechanistically, MIF overexpression promoted macrophage M2 polarization and TGF-β, CCL-24, and MIF secretion, and MIF recombinant protein facilitated M2 polarization, and TGF-β1 and CCL-24 production, contributing to CRSwNP recurrence.
CONCLUSIONS: Serum-specific cytokine signatures were associated with postoperative recurrence risk in CRSwNP. Elevated MIF enhanced macrophage M2 polarization and cytokine secretion, contributing to the recurrent mechanisms of CRSwNP.
NEW MATERIAL:A compound shown by formula I (R<1> and R<2> are 3-5C alkyl or alkenyl or R<1> and R<2> are mutually bonded alkylidene, cycloalkylidene, cycloalkylalkylidene or arylalkylidene). EXAMPLE:Ceftizoxime (3-propoxy-4-propoxymethylbenzoyloxy)methyl ester. USE:An antibacterial agent for oral administration. PREPARATION:A 3,4-disubstituted benzoic acid derivative shown by formula II is reacted with chloroiodomethane to give a compound shown by formula III (X is chlorine). Then this compound is reacted with sodium iodide to give an idomethyl ester derivative wherein X of the formula III is iodine. This derivative is reacted with ceftizoxime (metallic salt) shown by the formula IV in an anhydrous solvent preferably at <=0 deg.C.
<P>PROBLEM TO BE SOLVED: To provide a method for activating the immunity of fishes, particularly activating the immunity for parasitosis in the fishes in order to suppress the occurrence of dying in cultured fishes with the parasitosis.  <P>SOLUTION: The method for activating the immunity of the fishes comprises introducing a vasa-related gene of a parasite in the fishes into a parasite hatched larva, inhibiting the formation of a reproductive cell by RNA interference and parasitizing the resultant sterilized hatched larva on the fishes. The vasa-related gene of a parasite Neobenedeniagirellae on the fishes and a protein related to functions for forming the reproductive cell are provided. A double-stranded RNA is prepared by using a base sequence of a DNA of the vasa-related gene as a template. The hatched larva of the Neobenedeniagirellae in which the double-stranded RNA is introduced is provided and a vaccine for the fishes is composed of the hatched larva.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The present invention provides one new kind of gene controlling fungus growth and virulence and its utilization, and its coded protein has ankyrin repeat module. The gene in pyricular fungus is named as MgMBP1, and its whole length, cDNA, coded protein and promoter have the nucleotide sequences and amino acid sequences as shown. The gene is expressed in different hypha and infection stages, and its elimination results in obviously reduced pyricular fungus growth, infection default and virulence. It is also found that protein with consistency over 40 % to MgMBP1 exists also in grey botrytis, corn stem rot fungus, wheat bakanae fungus, etc. and may have the same function. The expression and modification of MgMBP1 and its homogenous protein, the cutting of the gene product and the nucleotide sequence of the promoter may be used as target sites in designing and screening new antifungal preparations.